Objectives: Adjuvant chemotherapy (AC) is the standard treatment for stage III colorectal cancer (CRC). However, its effectiveness is limited owing to adverse effects, particularly chemotherapy-induced peripheral neuropathy (CIPN). The objective of this study was to evaluate the real-world efficacy of Ninjin'yoeito (NYT), a traditional Kampo medicine, in improving chemotherapy tolerance and reducing adverse effects during AC with capecitabine plus oxaliplatin (CAPOX).
Kasahara et al. (Fri,) studied this question.